GO:0051967 negative regulation of synaptic transmission, glutamatergic: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051967 describes any process that stops, prevents, or reduces the frequency, rate, or extent of glutamatergic synaptic transmission, the main excitatory communication pathway in the brain [1,2].
• Negative regulation can occur presynaptically (reduced glutamate release) or postsynaptically (altered receptor function), and is essential for preventing excitotoxicity and shaping neural circuits [1,8].
• Key molecular players include presynaptic proteins such as synaptotagmins, metabotropic glutamate receptors (mGlu7), cannabinoid CB1 receptors, and scaffolding proteins like AKAP150 [2,3,4,6].
• Dysregulation of this process is linked to depression, anxiety, fear memory disorders, and chronic stress-related pathologies [3,5,6,7].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal testing of candidate genes in glutamatergic transmission [1,4,5].
• EDITGENE provides end-to-end services for generating and screening such models, accelerating mechanistic and therapeutic discovery [1,2,3,4,5,6,7,8].
Description
Glutamatergic synaptic transmission is the primary excitatory signaling mechanism in the mammalian central nervous system, and its precise negative regulation is critical for maintaining network stability and preventing pathological hyperexcitability [1,2]. The Gene Ontology term GO:0051967, negative regulation of synaptic transmission, glutamatergic, encompasses any process that reduces the frequency, rate, or extent of this transmission, thereby acting as a brake on excitatory drive [1,8]. This regulation occurs through diverse mechanisms, including presynaptic inhibition of glutamate release, postsynaptic modulation of receptor sensitivity, and alterations in synaptic protein composition [2,3,4].
negative regulation of synaptic transmission, glutamatergic At A Glance
| GO ID | GO:0051967 |
|---|---|
| GO term | negative regulation of synaptic transmission, glutamatergic |
| Ontology | biological_process |
| Synonym | down regulation of synaptic transmission, glutamatergic; down-regulation of synaptic transmission, glutamatergic; downregulation of synaptic transmission, glutamatergic; inhibition of synaptic transmission, glutamatergic |
| Major function | Reduces the frequency, rate, or extent of glutamatergic synaptic transmission, thereby modulating excitatory neural communication [1,2,8]. |
| Regulatory scope | Can act presynaptically (e.g., reduced glutamate release) or postsynaptically (e.g., altered receptor function) [2,3,4]. |
| Key molecular players | Synaptotagmins 2 and 4, mGlu7, CB1 receptors, AKAP150, DEPDC5, USP46, miR-186-5p [1,2,3,4,5,6]. |
| Associated diseases | Depression, anxiety, fear memory disorders, chronic stress-related pathologies [3,5,6,7]. |
What Is GO:0051967?
GO:0051967 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of glutamatergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glutamate. It includes mechanisms such as down-regulation or inhibition of glutamatergic signaling, and is a key homeostatic control point in neural circuits [1,2,8].
Why Is negative regulation of synaptic transmission, glutamatergic Important in Cell Biology?
Understanding negative regulation of glutamatergic transmission is essential because it serves as a fundamental brake on excitatory signaling, protecting against excitotoxicity and enabling adaptive behaviors such as fear extinction and stress coping [3,5,6]. Dysregulation of this process contributes to major neuropsychiatric and neurological disorders, making it a prime target for therapeutic intervention and a focus of intense research [3,5,6,7].
• Prevents excitotoxicity and neuronal damage by limiting excessive glutamate signaling [1,8].
• Shapes synaptic plasticity underlying learning, memory, and emotional regulation [3,4,6].
• Its impairment is linked to major depressive disorder and chronic stress vulnerability [3,5].
• Modulates fear memory reconsolidation, with implications for anxiety and PTSD.
• Involved in anxiety-like behaviors through cerebello-zona incerta circuits.
• Regulated by metabolic factors such as glucose and cholesterol, linking systemic physiology to brain function [2,8].
• Provides targets for pharmacological intervention, e.g., mGlu7 negative allosteric modulators.
• Serves as a model for studying homeostatic synaptic scaling and network stability [1,4].
• Enables CRISPR-based causal gene discovery in neuropsychiatric disease models [1,4,5].
• Offers biomarkers and therapeutic avenues for stress-related disorders.
What Happens During negative regulation of synaptic transmission, glutamatergic?
Presynaptic inhibition of glutamate release
In simple terms: The sending neuron releases less glutamate.
Presynaptic mechanisms reduce the probability of vesicle fusion or the number of release sites. For example, activation of cannabinoid CB1 receptors on glutamatergic terminals decreases neurotransmitter release, as shown in amygdalar cholecystokinin glutamatergic afferents to the nucleus accumbens. Similarly, glucose overload inhibits glutamatergic synaptic transmission via CREB-mediated regulation of synaptotagmins 2 and 4, which are key calcium sensors for vesicle fusion.
Postsynaptic modulation of receptor function
In simple terms: The receiving neuron becomes less responsive to glutamate.
Postsynaptic changes include altered receptor trafficking, phosphorylation, or desensitization. Cholesterol modulates both presynaptic and postsynaptic properties of excitatory synaptic transmission, affecting receptor function and membrane dynamics. Additionally, AKAP150-anchored PKA regulates synaptic transmission and plasticity in the lateral habenula, influencing postsynaptic excitability.
Regulation by intracellular signaling and protein interactions
In simple terms: Proteins inside the neuron interact to weaken the synapse.
DEPDC5 regulates the strength of excitatory synaptic transmission by interacting with ubiquitin-specific protease 46 (USP46), highlighting a role for protein stability and trafficking in negative regulation. MicroRNAs such as miR-186-5p also modulate synaptic transmission, as its inhibition restores synaptic transmission and neuronal network activity in a chronic stress model.
Metabotropic glutamate receptor signaling
In simple terms: Special glutamate receptors slow down the synapse.
Metabotropic glutamate receptors, particularly mGlu7, act as autoreceptors to inhibit glutamate release. Negative allosteric modulation of mGlu7 disrupts fear memory reconsolidation and glutamatergic signaling in rat and human brain tissue, demonstrating its role in negative regulation.
Circuit-level and behavioral consequences
In simple terms: These changes affect behavior and brain circuits.
Negative regulation of glutamatergic transmission in specific circuits modulates anxiety-like behaviors, as shown for cerebello-zona incerta circuits. It also influences depressive-like behavior through amygdalar-nucleus accumbens pathways.
Key Genes Involved in GO:0051967 negative regulation of synaptic transmission, glutamatergic
The following genes and proteins are experimentally implicated in negative regulation of glutamatergic synaptic transmission, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DEPDC5 | Regulates excitatory synaptic strength via interaction with USP46 | Mutations linked to epilepsy; target for synaptic transmission studies |
| SYT2 | Calcium sensor for vesicle fusion; downregulated by CREB under glucose overload | Mediates metabolic inhibition of glutamatergic transmission |
| SYT4 | Calcium sensor for vesicle fusion; downregulated by CREB under glucose overload | Mediates metabolic inhibition of glutamatergic transmission |
| CNR1 (CB1 receptor) | Presynaptic inhibition of glutamate release in amygdalar afferents | Modulates depressive-like behavior; target for mood disorder research |
| AKAP150 | Anchors PKA to regulate synaptic transmission and plasticity | Influences neuronal excitability and CRF neuromodulation in lateral habenula |
| PRKACA (PKA) | Phosphorylates synaptic targets to modulate transmission | Key kinase in plasticity and excitability |
| miR-186-5p | MicroRNA that inhibits synaptic transmission; inhibition restores activity | Biomarker and therapeutic target in chronic stress |
| GRM7 (mGlu7) | Metabotropic glutamate receptor mediating presynaptic inhibition | Target for fear memory reconsolidation and anxiety disorders |
| USP46 | Deubiquitinase interacting with DEPDC5 to regulate synaptic strength | Modulates protein stability in excitatory synapses |
| CREB | Transcription factor regulating synaptotagmin expression | Links metabolic state to synaptic transmission |
| CRF | Neuromodulator influencing synaptic transmission in lateral habenula | Stress-related modulation of excitability |
| Cholecystokinin (CCK) | Co-transmitter in glutamatergic afferents | Defines a specific circuit modulating depression-like behavior |
| Zona incerta neurons | Targets of cerebello-zona incerta circuits regulating anxiety | Circuit-level control of anxiety-like behaviors |
| Cholesterol | Modulates presynaptic and postsynaptic properties | Lipid regulation of excitatory transmission |
| Glucose | Metabolic substrate that inhibits transmission via CREB | Links energy status to synaptic function |
How Is negative regulation of synaptic transmission, glutamatergic Regulated?
Negative regulation of glutamatergic synaptic transmission is itself tightly regulated by diverse signaling pathways. Metabolic factors such as glucose and cholesterol modulate transmission through CREB-dependent regulation of synaptotagmins and membrane properties [2,8]. Protein-protein interactions, such as DEPDC5 with USP46, control synaptic strength via ubiquitination and trafficking. Kinases like PKA, anchored by AKAP150, phosphorylate targets to adjust excitability and plasticity. MicroRNAs, including miR-186-5p, provide post-transcriptional control, and their inhibition can restore transmission under chronic stress. Metabotropic receptors, notably mGlu7, act as autoreceptors to suppress glutamate release, and their allosteric modulation affects fear memory. Circuit-specific regulation by neuromodulators like CRF further tunes transmission in regions such as the lateral habenula.
negative regulation of synaptic transmission, glutamatergic and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DEPDC5 | Epilepsy, hyperexcitability | Knockout mouse or iPSC-derived neurons |
| CNR1 | Depression, mood disorders | Conditional knockout in amygdalar circuits |
| GRM7 | Fear memory disorders, anxiety | Point mutation or knockout in rat/human tissue |
| miR-186-5p | Chronic stress, depression | Overexpression or inhibition in stress models |
| AKAP150 | Stress-related disorders, excitability | Knock-in of phosphorylation mutants |
Depression and chronic stress
Impaired negative regulation of glutamatergic transmission contributes to depressive-like behavior. Cannabinoid CB1 receptors in amygdalar cholecystokinin glutamatergic afferents to the nucleus accumbens modulate depressive-like behavior, suggesting that loss of presynaptic inhibition may underlie mood disorders. In chronic stress models, inhibition of miR-186-5p restores synaptic transmission and neuronal network activity, highlighting a potential therapeutic strategy.
Anxiety and fear memory disorders
Negative allosteric modulation of mGlu7 disrupts fear memory reconsolidation and glutamatergic signaling in rat and human brain tissue, linking this receptor to anxiety and PTSD. Additionally, cerebello-zona incerta circuits regulate anxiety-like behaviors through plasticity-dependent mechanisms, indicating that circuit-specific negative regulation is critical for emotional control.
Epilepsy and excitotoxicity
DEPDC5 regulates the strength of excitatory synaptic transmission by interacting with USP46, and mutations in DEPDC5 are associated with epilepsy, suggesting that impaired negative regulation can lead to hyperexcitability. Excessive glutamatergic transmission is a known driver of excitotoxicity, and mechanisms that normally dampen it are protective [1,8].
From negative regulation of synaptic transmission, glutamatergic-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DEPDC5 increase excitatory transmission? | DEPDC5 knockout in neurons |
| Does mGlu7 point mutation affect fear reconsolidation? | GRM7 point-mutation knock-in rat |
| Can miR-186-5p inhibition restore transmission in chronic stress? | miR-186-5p overexpression or sponge in stress models |
| How does AKAP150 anchoring regulate PKA signaling? | AKAP150 knock-in with disrupted PKA binding |
| Does CB1 receptor deletion alter depressive-like behavior? | Conditional CB1 knockout in CCK+ neurons |
| What is the role of synaptotagmin 2/4 in glucose-mediated inhibition? | SYT2/SYT4 knockout or overexpression |
How to Study the negative regulation of synaptic transmission, glutamatergic Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Synaptic currents and excitability | Quantify EPSCs in knockout or mutant neurons [1,3,6] |
| Co-immunoprecipitation | Protein-protein interactions | Validate DEPDC5-USP46 binding |
| Western blot | Protein expression and phosphorylation | Assess CREB and synaptotagmin levels |
| RNA-seq | Transcriptome changes | Identify genes altered in disease models |
| Small RNA-seq | MicroRNA expression | Profile miR-186-5p in chronic stress |
| Calcium imaging | Neuronal activity | Measure circuit activity in anxiety models |
| Optogenetics | Circuit-specific manipulation | Dissect amygdalar pathways |
| Behavioral assays | Depressive-like and anxiety-like behaviors | Link synaptic changes to behavior [3,5,6,7] |
Electrophysiology
Patch-clamp recordings measure spontaneous and evoked excitatory postsynaptic currents (EPSCs) to quantify changes in glutamatergic transmission. This method directly assesses the frequency, amplitude, and kinetics of synaptic events, as used in studies of DEPDC5, CB1 receptors, and mGlu7 [1,3,6].
Molecular and biochemical assays
Co-immunoprecipitation, Western blotting, and ubiquitination assays reveal protein interactions and post-translational modifications, such as DEPDC5-USP46 interaction and CREB-mediated regulation of synaptotagmins [1,2].
Transcriptomics and microRNA profiling
RNA-seq and small RNA-seq identify changes in gene expression, including microRNAs like miR-186-5p, that regulate glutamatergic transmission under stress or disease conditions.
Imaging and circuit mapping
Fluorescence imaging, calcium indicators, and optogenetics map circuit-specific transmission and plasticity, as applied to cerebello-zona incerta circuits and amygdalar-nucleus accumbens pathways [3,7].
How CRISPR Can Be Used to Study GO:0051967 negative regulation of synaptic transmission, glutamatergic
Knockout
CRISPR knockout of genes such as DEPDC5, CNR1, or GRM7 in cell lines or primary neurons can abolish their function, allowing researchers to test whether they are required for negative regulation of glutamatergic transmission [1,3,6].
Point Mutation
Introducing precise point mutations, e.g., in GRM7 to mimic disease-associated variants, enables study of altered receptor function and its impact on synaptic transmission and behavior.
Knock-in
Knock-in of tags or reporters (e.g., fluorescent tags on SYT2 or AKAP150) allows real-time visualization of protein localization and dynamics at glutamatergic synapses [2,4].
Overexpression
Overexpression of microRNAs like miR-186-5p or proteins such as USP46 can enhance negative regulation, providing gain-of-function models to study synaptic strength and network activity [1,5].
How EDITGENE Supports negative regulation of synaptic transmission, glutamatergic Research
Researchers studying negative regulation of synaptic transmission, glutamatergic-related genes often need to determine whether a candidate gene is causally involved in modulating excitatory signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous mechanistic and therapeutic studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of synaptic transmission, glutamatergic research.
Frequently Asked Questions About negative regulation of synaptic transmission, glutamatergic
What is GO:0051967?
GO:0051967 is the Gene Ontology term for negative regulation of synaptic transmission, glutamatergic, describing any process that reduces the frequency, rate, or extent of glutamatergic signaling between neurons [1,2].
What genes are involved in negative regulation of glutamatergic synaptic transmission?
Key genes include DEPDC5, SYT2, SYT4, CNR1, AKAP150, GRM7, and microRNAs such as miR-186-5p, as shown in recent studies [1,2,3,4,5,6].
How is glutamatergic synaptic transmission negatively regulated?
It can be negatively regulated presynaptically by reducing glutamate release (e.g., via CB1 or mGlu7 receptors) or postsynaptically by altering receptor function and signaling [3,6,8].
Why is negative regulation of glutamatergic transmission important?
It prevents excitotoxicity, maintains network stability, and shapes behaviors such as fear extinction and stress coping; its dysregulation is linked to depression, anxiety, and epilepsy [1,3,5,6,7].
What diseases are associated with impaired negative regulation of glutamatergic transmission?
Depression, chronic stress, anxiety disorders, fear memory disorders, and epilepsy have been linked to dysfunction in this process [1,3,5,6,7].
How can CRISPR be used to study negative regulation of glutamatergic transmission?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in neurons and animal models [1,3,4,5,6].
What methods measure glutamatergic synaptic transmission?
Patch-clamp electrophysiology, calcium imaging, and molecular assays such as co-immunoprecipitation and RNA-seq are commonly used [1,2,3,5,7].
What is the role of mGlu7 in glutamatergic transmission?
mGlu7 is a metabotropic glutamate receptor that acts as an autoreceptor to inhibit glutamate release; its negative allosteric modulation affects fear memory reconsolidation.
How does chronic stress affect glutamatergic transmission?
Chronic stress can impair synaptic transmission, but inhibition of miR-186-5p restores neuronal network activity in stress models.
Can negative regulation of glutamatergic transmission be targeted therapeutically?
Yes, modulating receptors like mGlu7 or microRNAs such as miR-186-5p shows promise for treating depression, anxiety, and fear-related disorders [5,6].
Conclusion
GO:0051967, negative regulation of synaptic transmission, glutamatergic, is a critical biological process that dampens excitatory signaling to protect neural circuits and shape behavior. Research has identified diverse molecular players, from presynaptic receptors to intracellular signaling proteins and microRNAs, and linked their dysfunction to major neuropsychiatric and neurological disorders [1,2,3,4,5,6,7,8]. Leveraging CRISPR-based models and multi-omics approaches will continue to unravel the mechanisms and therapeutic potential of this process.
References
- 1. Cerullo MS et al.. 2025. DEPDC5 regulates the strength of excitatory synaptic transmission by interacting with ubiquitin-specific protease 46.. Neurobiol Dis 212:106985 PMID: 40467011
- 2. Ripoli C et al.. 2020. Glucose Overload Inhibits Glutamatergic Synaptic Transmission: A Novel Role for CREB-Mediated Regulation of Synaptotagmins 2 and 4.. Front Cell Dev Biol 8:810 PMID: 32974347
- 3. Shen CJ et al.. 2019. Cannabinoid CB(1) receptors in the amygdalar cholecystokinin glutamatergic afferents to nucleus accumbens modulate depressive-like behavior.. Nat Med 25(2):337-349 PMID: 30643290
- 4. Simmons SC et al.. 2023. AKAP150-anchored PKA regulation of synaptic transmission and plasticity, neuronal excitability and CRF neuromodulation in the lateral habenula.. bioRxiv PMID: 38106086
- 5. Rodrigues B et al.. 2025. MiR-186-5p inhibition restores synaptic transmission and neuronal network activity in a model of chronic stress.. Mol Psychiatry 30(3):1034-1046 PMID: 39237722
- 6. Ciobanu AC et al.. 2026. Negative allosteric modulation of mGlu7 disrupts fear memory reconsolidation and glutamatergic signaling in rat and human brain tissue.. Mol Psychiatry 31(2):976-986 PMID: 41436583
- 7. Zhao Y et al.. 2025. Dual and plasticity-dependent regulation of cerebello-zona incerta circuits on anxiety-like behaviors.. Nat Commun 16(1):3339 PMID: 40199879
- 8. Korinek M et al.. 2020. Cholesterol modulates presynaptic and postsynaptic properties of excitatory synaptic transmission.. Sci Rep 10(1):12651 PMID: 32724221
